MediLink presents YL201 (B7H3 ADC) at ESMO 2024, with over 6-months PFS in SCLC, and showing pan-tumor benefits

• The first publication of clinical data for YL201, featured in an oral presentation at ESMO 2024.
• Encouraging antitumor activity of YL201 in multiple solid tumor types, including SCLC, NPC, and wild-type NSCLC, from Phase I escalation and expansion results.
• In extensive-stage SCLC patients, ORR was 68.1% and mPFS was 6.2 months.

SUZHOU, China, Sept. 14, 2024 /PRNewswire/ -- MediLink Therapeutics (MediLink) today presented clinical data for YL201, a novel B7H3-targeting antibody drug conjugate (ADC) developed based on MediLink's Tumor Microenvironment Activable LINker-payload (TMALIN®) platform, at the European Society for Medical Oncology (ESMO) Congress. This is the first disclosure of clinical data for YL201 featured in an oral presentation.